GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » ROE % Adjusted to Book Value

Oruka Therapeutics (FRA:HQ1) ROE % Adjusted to Book Value : 0.00% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics ROE % Adjusted to Book Value?

Oruka Therapeutics's ROE % for the quarter that ended in Mar. 2024 was 0.00%. Oruka Therapeutics's PB Ratio for the quarter that ended in Mar. 2024 was N/A. Oruka Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was N/A.

Oruka Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Oruka Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics ROE % Adjusted to Book Value Chart

Oruka Therapeutics Annual Data
Trend Dec24
ROE % Adjusted to Book Value
-

Oruka Therapeutics Semi-Annual Data
Mar24
ROE % Adjusted to Book Value -

Competitive Comparison of Oruka Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Oruka Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oruka Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's ROE % Adjusted to Book Value falls into.


;
;

Oruka Therapeutics ROE % Adjusted to Book Value Calculation

Oruka Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Oruka Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oruka Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Oruka Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
ATXS ATAI GLUE PHAT PRME AURA OLMA ALDX ERAS CYDY VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
ORKA:USA HQ1:Germany
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Website
https://www.orukatx.com
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines